Goldman Sachs Adjusts Price Target on Agilent Technologies to $150 From $170, Maintains Buy Rating

Clinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer Prevention

Clinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to Dementia

Endpoints NewsIn Washington, biotech's China hawks are winning the conversation

Clinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future Strains

Endpoints NewsIndustry seeks more clarity on commissioner's voucher program

BioWorldMoney raised by biopharma

BioWorldBiopharma money raised: Jan. 1-June 4, 2026

BioWorldBioWorld and Nasdaq stock indices

Endpoints NewsHouse committee directs FDA to speed up IND sign-off process

FierceBiotechExecutive Interviews at Fierce Biotech Week 2026

BioWorldBiopharma money raised by month in 2026 (US$M)

BioPharma DiveStudy data convince Lundbeck to push new migraine drug forward